IXICO (LSE:IXI) Gross-Profit-to-Asset % : 16.61% (As of Mar. 2024)

View and export this data going back to 1996. Start your Free Trial

What is IXICO Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. IXICO's annualized Gross Profit for the quarter that ended in Mar. 2024 was £2.04 Mil. IXICO's average Total Assets over the quarter that ended in Mar. 2024 was £12.28 Mil. Therefore, IXICO's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 was 16.61%.

IXICO Gross-Profit-to-Asset % Historical Data

The historical data trend for IXICO's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IXICO Gross-Profit-to-Asset % Chart

IXICO Annual Data

Trend

Sep13

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

46.98

55.36

45.49

36.26

23.66

IXICO Semi-Annual Data
	Mar14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															33.70	41.03	20.73	26.76	16.61

Competitive Comparison of IXICO's Gross-Profit-to-Asset %

For the Biotechnology subindustry, IXICO's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IXICO's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IXICO's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where IXICO's Gross-Profit-to-Asset % falls into.

IXICO Gross-Profit-to-Asset % Calculation

IXICO's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Sep. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Sep. 2023 )	/	( (Total Assets (A: Sep. 2022 )	+	Total Assets (A: Sep. 2023 ))	/ count )
	=	3.27	/	( (14.655	+	12.99)	/ 2 )
	=	3.27	/	13.8225
	=	23.66 %

IXICO's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Mar. 2024 )	/	( (Total Assets (Q: Sep. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
	=	2.04	/	( (12.99	+	11.57)	/ 2 )
	=	2.04	/	12.28
	=	16.61 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Mar. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

IXICO Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of IXICO's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

IXICO (LSE:IXI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IXICO PLC (LSE:IXI) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

PHYOF:USA

Address

15 Long Lane, 4th Floor, Griffin Court, London, GBR, EC1A 9PN

Website

https://www.ixico.com

IXICO PLC is a UK-based company engaged in providing clinical trial services and technology to evaluate imaging endpoints to pharmaceutical companies. Its therapeutic areas include Alzheimer's, Parkinson's, Huntington's, Multiple Sclerosis, Progressive Supranuclear Palsy, and Other Rare Neurological Diseases. Services offered by the company are Early Phase Clinical Development, Late Phase Clinical Development, Post-Marketing, and Consultancy. The company's geographical segments include the United States, Switzerland, the United Kingdom, the Netherlands, Ireland and other- Europe. The Company work with healthcare organizations across the entire clinical research journey, for drug development analytics, medical imaging operations and post-marketing surveillance.

IXICO (LSE:IXI) Headlines

No Headlines